Alternative LDL Cholesterol safely and effectively lowers risk of ASCVD instead of high intensity statins: JAMA

For high-risk patients with
atherosclerotic cardiovascular disease (ASCVD), intensive lowering of
low-density lipoprotein (LDL) cholesterol levels is advised. High-intensity
statins are the recommended first-line treatment for such conditions. However,
high-intensity statins can have some side effects and lead to poor long-term
adherence. The previous literature suggested a combination of
moderate-intensity statin with LDL cholesterol-lowering drugs to reduce the
side effects and improve tolerance. Most of the previous research has explored
the impact of such a combination on preventing adverse cardiovascular events.
As there is limited research on the effects of LDL cholesterol-lowering drugs
on effectiveness and safety, researchers conducted a systematic review and
meta-analysis on the long-term efficacy and safety of an alternative LDL
cholesterol–lowering strategy vs. high-intensity statin strategy in patients
with ASCVD in randomized clinical trials. 

A literature search was carried
out from databases like PubMed, Embase, and other websites (ClinicalTrials.gov,
European Society of Cardiology, tctMD) to include randomized clinical
trials comparing an alternative LDL cholesterol–lowering strategy vs. a
high-intensity statin strategy in patients with ASCVD, with the presence of
cardiovascular events as endpoints. Many studies were filtered, and two trials
were deemed eligible. They were the RACING trial and the LODESTAR trial. The
moderate-intensity statin with ezetimibe combination therapy in the RACING
trial and the treat-to-target strategy in the LODESTAR trial were classified as
alternative LDL cholesterol-lowering strategies. The primary endpoint was
to assess a 3-year composite of all-cause death, myocardial infarction, stroke,
or coronary revascularization, while the secondary endpoints comprised clinical
efficacy and safety endpoints.

Findings:

• About 8180 patients with ASCVD, with a mean [SD]
  age of 64.5 [9.8] years, were analyzed.
• There were 2182 [26.7%] female and 5998 males
  [73.3%]) in the study.
• No difference was observed in the primary
  endpoint rate between the alternative strategy and high-intensity statin
  strategy groups (7.5% vs 7.7%).
• The mean (SD) LDL cholesterol level during
  treatment was 64.8 (19.0) mg/dL in the alternative strategy group and 68.5
  (20.7) mg/dL in the high-intensity statin strategy group (P < .001).
• However, the alternative strategy group had a
  lower rate of new-onset diabetes (10.2% vs 11.9%).
• The initiation of antidiabetic medication for
  new-onset diabetes was slow (6.5% vs 8.2%).
• The intolerance-related discontinuation or dose
  reduction of assigned therapy was also less (4.0% vs 6.7%).

Thus, the study concluded that an
alternative LDL cholesterol-lowering strategy has a comparable efficacy
regarding mortality or adverse cardiovascular events in ASCVD patients.
Additionally, it also exhibited a reduction in LDL cholesterol levels and risk
for new-onset diabetes and intolerance.

Further reading: Lee Y, Hong
B, Yun KH, et al. Alternative LDL Cholesterol–Lowering Strategy vs
High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A
Systematic Review and Individual Patient Data Meta-Analysis. JAMA
Cardiol. Published online November 20, 2024.
doi:10.1001/jamacardio.2024.3911